# US 2016/0354436 A1 · Compositions and Formulations for Increasing Renal Function and Treatment and Prevention of Renal Diseases, and Methods of Production and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354436 A1
- Document ID: US20160354436A1
- Status: Published application
- Kind: A1
- Application number: 15/024,648
- Filed: 2014-09-25
- Published: 2016-12-08
- Earliest claimed: 2013-09-25
- Assignees: Pronutria Biosciences, Inc.
- Applicants: PRONUTRIA Biosciences, Inc.
- Inventors: Alison WILLIAMS; Nathaniel W. SILVER; Andrew DOWNEY; David V. ERBE; Michael J. HAMILL; David Arthur BERRY
- Web page: https://patentgrep.com/patent/US20160354436A1

## CPC

- A61K 38/1709: {from mammals}
- A23L 2/66: Proteins
- A23L 33/17: Amino acids, peptides or proteins
- A23L 33/175: Amino acids
- A23L 33/18: Peptides; Protein hydrolysates
- A23L 33/195: Proteins from microorganisms
- A23L 33/30: {Dietetic or nutritional methods, e.g. for losing weight (A23L33/10 takes precedence)}
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/164: {from bacteria}
- A61K 38/168: {from plants}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1703: {from vertebrates}
- A61K 38/1767: {from invertebrates}
- A61K 38/38: Albumins
- A61K 38/45: Transferases (2)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/06: Anabolic agents (androgens A61P5/26)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/06: for tuberculosis
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Y 207/04003: Adenylate kinase (2.7.4.3)
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- G01N 33/6806: {Determination of free amino acids}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/50: Mutagenesis
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- G01N 2500/00: Screening for compounds of potential therapeutic value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.

## Claims

### Claim at position 1

-44. (canceled)

### Claim 45

A nutritive formulation for the treatment or prevention of a muscle wasting disease, disorder or condition in a human subject suffering from a renal disease, comprising an isolated nutritive polypeptide comprising an amino acid sequence at least about 90% identical over at least about 50 amino acids to a polypeptide sequence selected from the group consisting of SEQID 00001-03909; wherein the nutritive polypeptide is present in an amount sufficient to provide a nutritional benefit to a human subject having or at risk of having reduced protein absorption capacity; wherein the isolated nutritive polypeptide has an aqueous solubility at pH 7 of at least 12.5 g/L and wherein the isolated nutritive polypeptide has a simulated gastric digestion half-life of less than 30 minutes.

### Claim 46 (depends on 45)

The formulation of claim 45, wherein the polypeptide sequence comprises a ratio of essential amino acid residues to total amino acid residues of at least 34% and wherein the polypeptide sequence is nutritionally complete.

### Claim 47 (depends on 45)

The formulation of claim 45, wherein the nutritive polypeptide is formulated in a pharmaceutically acceptable carrier, or wherein the nutritive polypeptide is formulated in or as a food or a food ingredient; or wherein the nutritive polypeptide is formulated in or as a beverage or a beverage ingredient.

### Claim 48 (depends on 45)

The formulation of claim 45, wherein the amino acid sequence encodes an enzyme having a primary activity, and wherein the nutritive polypeptide substantially lacks the primary activity.

### Claim 49 (depends on 45)

The formulation of claim 45, further comprising a component selected from a tastant, a protein mixture, a polypeptide, a peptide, a free amino acid, a carbohydrate, a lipid, a mineral or mineral source, a vitamin, a supplement, an organism, a pharmaceutical, and an excipient.

### Claim 50 (depends on 45)

The formulation of claim 45, wherein the formulation is present as a liquid, semi-liquid or gel in a volume not greater than about 500 ml or as a solid or semi-solid in a total mass not greater than about 200 g.

### Claim at position 8

-64. (canceled)

### Claim 65

A method of treating or reducing the severity of a renal disease in a human subject, comprising administering to the human subject a nutritional formulation in an amount sufficient to treat or prevent the renal disease, wherein the nutritional formulation comprises an isolated nutritive polypeptide comprising an amino acid sequence at least about 90% identical over at least about 50 amino acids to a polypeptide sequence selected from the group consisting of SEQID 00001-03909.

### Claim 66 (depends on 65)

The method of claim 65, wherein the isolated nutritive polypeptide has an aqueous solubility at pH 7 of at least 12.5, 20, 30, 50, or 100 g/L.

### Claim 67 (depends on 65)

The method of claim 65, wherein the isolated nutritive polypeptide has a simulated gastric digestion half-life of less than 2, 10, 30, or 60 minutes.

### Claim 68 (depends on 65)

The method of claim 65, wherein the isolated nutritive polypeptide does not form insoluble aggregates at 95° C., pH 7.1, when present at 10 mg/ml.

### Claim 69 (depends on 65)

The method of claim 65, wherein the formulation further comprises a pharmaceutically acceptable carrier.

### Claim 70 (depends on 65)

The method of claim 65, wherein the formulation is present as a liquid, semi-liquid or gel in a volume not greater than about 500 ml or as a solid or semi-solid in a total mass not greater than about 200 g; and wherein the formulation is substantially free of non-comestible products.

### Claim 71 (depends on 65)

The method of claim 65, wherein the formulation further comprises a component selected from a tastant, a protein mixture, a polypeptide, a peptide, a free amino acid, a carbohydrate, a lipid, a mineral or mineral source, a vitamin, a supplement, an organism, a pharmaceutical, and an excipient.

### Claim 72 (depends on 65)

The method of claim 65, wherein the human subject is at risk of developing malnutrition or protein malnutrition.

### Claim 73 (depends on 65)

The method of claim 65, wherein the human subject has chronic renal failure, acute renal failure, glomerulonephritis, glomerulonephrosis, tubular nephritis, interstitial nephritis, or nephrotic syndrome.

### Claim 74 (depends on 65)

The method of claim 65, wherein the human subject has end-stage renal disease or a nephrotic syndrome.

### Claim 75 (depends on 65)

The method of claim 65, wherein the human subject has a urea cycle disorder.

### Claim 76 (depends on 65)

The method of claim 65, wherein the human subject suffers from a muscle wasting condition.

### Claim 77 (depends on 65)

The method of claim 65, wherein the nutritional formulation is administered as an adjunct to administration of a pharmaceutical composition.

### Claim 78 (depends on 65)

The method of claim 65, wherein the human subject is suffering from a renal disease and has received one or more doses of a pharmaceutical composition, wherein i) the disease, disorder or condition or ii) the administration of the pharmaceutical composition, or both i) and ii) increases a risk of loss of muscle mass and/or muscle function.
